Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
| Older periods | Sep '23 | Dec '23 | Mar '24 | Jun '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.03 |
P/S ratio |
13.59 | 3.07 | 3.85 | 0.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.55) | (3.54) | (1.64) | (1.59) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
12.92 | 2.30 | 4.25 | 1.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.71) | (0.21) | (0.46) | (0.19) | |
EV/FCF |
(0.71) | (0.21) | (0.46) | (0.19) | |
Quick Ratio |
0.08 | 0.10 | 0.04 | 0.02 | |
Current Ratio |
0.18 | 0.14 | 0.10 | 0.08 | |
Net Debt/EBITDA |
0.10 | 0.37 | 0.09 | 0.09 | |
Debt/Assets |
20.96% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
(0.04) | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.08 | 0.16 | 0.14 | 0.28 | |
Operating CF/Net income |
(0.55) | 0.35 | 1.74 | (0.57) | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Interest Coverage |
(300.07) | (421.63) | (263.26) | (136.48) | |
Research and Development Expense of Revenue |
2,468.47% | 906.28% | 608.81% | 256.91% | |
Selling, General and Administrative Expense of Revenue |
735.71% | 420.52% | 536.96% | 677.93% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
239.90% | 147.63% | 164.94% | 231.91% | |
Graham Net Nets |
(1.16) | (4.96) | (4.36) | (18.18) | |
Graham Number |
5,713.09 | 4,399.43 | 2,003.48 | 0.00 | |
Earnings Yield |
(225.97%) | (556.60%) | (731.20%) | 3,246.71% | |
Free Cash Flow Yield |
(134.22%) | (353.67%) | (239.50%) | (857.17%) | |
Revenue per Share |
11.53 | 17.05 | 5.70 | 2.40 | |
Operating CF per Share |
(163.32) | (49.90) | (45.69) | (6.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(163.32) | (49.90) | (45.69) | (6.21) | |
Cash per Share |
73.41 | 78.22 | 5.16 | 1.88 | |
Shareholders Equity per Share |
(863.98) | (874.93) | (325.83) | (179.65) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(863.98) | (874.93) | (325.83) | (179.65) | |
Free Cash Flow |
(5.75) | (1.91) | (4.64) | (0.97) | |
Working Capital |
(29.14) | (33.52) | (33.17) | (28.18) | |
Net Current Asset Value |
(30.44) | (33.52) | (33.17) | (28.18) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.45 | 0.58 | 0.88 | 0.31 | |
Average Payables |
7.64 | 10.01 | 10.62 | 11.06 | |
Average Assets |
23.36 | 14.08 | 13.63 | 7.14 | |
Average Common Equity |
(11.27) | (22.06) | (26.88) | (37.66) |
Columns are period end dates